Instead of extracting T-cells and engineering them in a lab, researchers have delivered mRNA directly into circulating immune ...

AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company focused on discovery and development of innovative and proprietary cell-based therapeutic ...

The FDA approves INCY's Monjuvi in combination with rituximab and lenalidomide for relapsed/refractory follicular lymphoma, its second approved indication.

During a live event, John S. Renshaw, MD, and other oncologists discussed various trials of novel regimens for patients with ...

KITE-363, a dual-targeting CAR T-cell therapy, shows a strong safety profile and high responses in patients who have highly ...

Incyte said it received approval from the Food and Drug Administration for monjuvi, in combination with rituximab and lenalidomide, as a treatment for follicular lymphoma.

Results show the regimen of epcoritamab plus R-ICE could serve most patients as a bridge to either autologous stem cell ...

The phase 1b trial’s primary endpoints are the occurrence of adverse events, including dose-limiting toxicities, and the ...

The antigens detected and antibodies used were CD45/HLE-1, CD2/Leu-5b, CD4/Leu-3a and Leu-3b, CD5/Leu-1, CD7/Leu-9, CD8/Leu-2a, CD10/CALLA, CD14/Leu-M3, CD19/Leu-12, CD20/Leu-16, CD22(G2b)/Leu-14 ...

Cosmos token shows resilience despite rejection at key resistance level, bouncing back with a 1.4% hourly gain.

The token’s rebound was bolstered by technicals, as well as growing Avalanche-based projects making exposure to AVAX more ...

The dual-targeting CAR T-cell therapy KITE-363 showed positive response rates and manageable side effects in relapsed or ...